Lucien Hordijk is a Dutch investigative journalist. He has been covering the pharmaceutical industry for seven years. He reported on skyrocketing prices, 'hijacking' of old molecules, regulatory capture, generic shortages, orphan medicines, biosimilars and industry lobbying. His investigations led to international coverage in the British Medical Journal, The Financial Times, The Wall Street Journal and Reuters.

Basic information

Lucien Hordijk
Pharmaceutical industry

Supported projects

Behind The Pledge - How EU money is spent for Covid19 drugs

  • Healthcare
  • Industry

BRUSSELS - How did we come to pay gold for a drug whose effectiveness has not been proven? This is the story of Remdesivir, a drug developed by the American company Gilead Sciences with large public funds to combat Ebola, and in July approved by the European Medicines Agency with "conditional authorisation" as the first antiviral against Covid 19.